17.74
-0.26 (-1.44%)
| Previous Close | 18.00 |
| Open | 17.78 |
| Volume | 189,912 |
| Avg. Volume (3M) | 1,251,146 |
| Market Cap | 2,093,375,360 |
| Price / Sales | 612.75 |
| Price / Book | 5.24 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2026 |
| Operating Margin (TTM) | -1,525.50% |
| Diluted EPS (TTM) | -3.01 |
| Quarterly Revenue Growth (YOY) | 184.40% |
| Total Debt/Equity (MRQ) | 1.55% |
| Current Ratio (MRQ) | 10.49 |
| Operating Cash Flow (TTM) | -152.68 M |
| Levered Free Cash Flow (TTM) | -117.16 M |
| Return on Assets (TTM) | -33.54% |
| Return on Equity (TTM) | -69.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Immunome, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | 1.17 |
Select this tab to load the latest available analysis.
|
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.48% |
| % Held by Institutions | 83.28% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Redmile Group, Llc | 30 Jun 2026 | 4,911,590 |
| Primecap Management Co/Ca/ | 30 Jun 2026 | 4,581,431 |
| Enavate Sciences Gp, Llc | 30 Jun 2026 | 3,613,799 |
| Silverarc Capital Management, Llc | 30 Jun 2026 | 2,017,009 |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |